An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
Journal Title: Journal of Vaccines & Immunization - Year 2014, Vol 2, Issue 1
Abstract
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumption for non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.
Authors and Affiliations
Moberley SA, Andrews RM
Keywords
Related Articles
- EP ID EP566670
- DOI 10.14312/2053-1273.2014-1
- Views 48
- Downloads 0
Impact of strategies and activities for reducing morbidity and mortality of vaccine-preventable diseases in Oman: A status report
Immunization is the only child survival strategy which alone averts two to three million deaths each year. This has been possible because of high coverages achieved by many countries in the world. Still nearly 1.5 millio...
Influenza and pneumococcal vaccination in hospitalized adults with pandemic (H1N1) 2009: Immunization practices and impact on clinical presentation and outcomes
The purpose of this study was to determine vaccination rates against influenza and pneumococcus in a large cohort of adults hospitalized with confirmed influenza A(H1N1) pdm09 infection, and to identify differences in cl...
From package to protection: how do we close global coverage gaps to optimize the impact of vaccination?
The success of every vaccination program is dependent upon reaching and sustaining the target coverage rates. Vaccination programs are currently facing coverage gaps where target coverages are never reached and may also...
Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardi...
Routine immunization services in Africa: back to basics
National immunization programmes were created as a sequel to smallpox eradication when countries undertook mass immunization campaigns and other control measures to fight the disease. As smallpox came near to eradication...